dr. (Maiwenn) MJ Al

All publications (83)

• Article (73)

  • Scholarly Publication (68)

    • M.S. Holleman, H. van Tinteren, H.J.M. Groen, M.J. Al & C.A. Uyl - de Groot (2019). First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Oncotargets and Therapy, 12, 1413-1421. doi: 10.2147/ott.S189438
    • M.G. Franken, I. Corro Ramos, J. Los & M.J. Al (2018). The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 19 (31). doi: 1186/s12875-018-0714-9 [go to publisher's site]
    • E. Alemao, S. Johal, M.J. Al & M.P.M.H. Rutten - van Molken (2018). Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. Value in Health, 21 (2), 193-202. doi: 10.1016/j.jval.2017.05.020
    • E. Alemao, M.J. Al, A.A. Boonen, M.D. Stevenson, S. Verstappen, K. Michaud, M.E. Weinblatt & M.P.M.H. Rutten - van Molken (2018). Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS One (print), 13 (10). doi: 10.1371/journal.pone.0205013
    • N.C. Buyukkaramikli, S. de Groot, R. Riemsma, D. Fayter, N. Armstrong, P. Portegijs, S. Duffy, J. Kleijnen & M.J. Al (2018). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0708-4
    • I. Corro Ramos, G.A.K. van Voorn, P. Vemer, T. Feenstra & M.J. Al (2017). A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. Value in Health, 20 (8), 1041-1047. doi: 10.1016/j.jval.2017.04.016
    • N. Büyükkaramikli, H.M. Blommestein, R. Riemsma, N. Armstrong, F.J. Clay, J. Ross, G. Worthy, J.L. Severens, J. Kleijnen & M.J. Al (2017). Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print).
    • N.C. Büyükkaramikli, S. de Groot, D. Fayter, R. Wolff, N. Armstrong, L. Stirk, G. Worthy, F.G. Albuquerque de Almeida, J. Kleijnen & M.J. Al (2017). Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics (Print). doi: 10.1007/s40273-017-0581-6
    • I. Corro Ramos, S. Lhachimi, A. Gerber-Grote & M.J. Al (2016). Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework. Medical Decision Making. doi: 10.1177/0272989X16636856
    • J. Bindels, B. Ramaekers, I. Corro Ramos, L. Mohseninejad, S. Knies, J. Grutters, M. Postma, M.J. Al, T. Feenstra & M. Joore (2016). Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. Pharmacoeconomics (Print), 34 (3), 315-322. doi: 10.1007/s40273-015-0346-z
    • E. Alemao, H. Cawston, F. Bourhis, M.J. Al, M.P.M.H. Rutten - van Molken, K.P. Liao & D. Solomon (2016). Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. Rheumatology, 55 (5), 809-816. doi: 10.1093/rheumatology/kev427
    • E. Alemao, S. Joo, H. Kawabata, M.J. Al, P.D. Allison, M.P.M.H. Rutten - van Molken, M.L. Frits, C.K. Iannaccone, N.A. Schadik & M.E. Weinsblatt (2016). Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. Arthritis Care & Research, 68 (3), 308-317. doi: 10.1002/acr.22678
    • L.T. Burgers, W.K. Redekop, M.J. Al, S.K. Lhachimi, N. Armstrong, S. Walker, C. Rothery, M. Westwood & J.L. Severens (2016). Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. European Journal of Health Economics (HEPAC), 1-12. doi: 10.1007/s10198-016-0824-z
    • H.M. Blommestein, N. Armstrong, S. Ryder, S. Deshpande, G. Worthy, C. Noake, R. Riemsma, J. Kleijnen, J.L. Severens & M.J. Al (2016). Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics (Online), 34 (1), 23-31. doi: 10.1007/s40273-015-0318-3
    • R. Riemsma, I. Corro Ramos, R. Birnie, N.C. Buyukkaramikli, N. Armstrong, S. Ryder, S. Duffy, G. Worthy, M.J. Al, J.L. Severens & J. Kleijnen (2016). Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technology Assessment, 20 (17). doi: 10.3310/hta20170
    • P. Vemer, I. Corro Ramos, G.A.K. van Voorn, M.J. Al & T. Feenstra (2016). AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users. Pharmacoeconomics (Print), 34 (4), 349-361. doi: 10.1007/s40273-015-0327-2
    • K.M. Goor, J.G. Gaultney, P. van Houten, A.S. Wagg, S.A. Huygens, M.M. Nielen, C.P. Albers-Heitner, W.K. Redekop, M.P.M.H. Rutten - van Molken & M.J. Al (2015). Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. PLoS One (print), 10 (10). doi: 10.1371/journal.pone.0138225
    • O. Mandrik, I. Corro Ramos, S. Knies, M.J. Al & J.L. Severens (2015). Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Management and Research (online), 2015 (7), 279-289. doi: 10.2147/CMAR.S79258
    • N. Armstrong, L.T. Burgers, S. Deshpande, M.J. Al, R. Riemsma, S.R. Vallabhaneni, P. Holt, J.L. Severens & J. Kleijnen (2015). The use of fenestrated and branched endovascular aneurysm repairfor juxtarental and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 18 (70). doi: 10.3310/hta18700
    • I. Corro Ramos, M.P.M.H. Rutten - van Molken & M.J. Al (2015). Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. Value in Health, 18 (1), 100-109. doi: 10.1016/j.jval.2014.09.003.
    • P. Whiting, M.J. Al, L.T. Burgers, M. Westwood, S. Ryder, M. Hoogendoorn, N. Armstrong, A. Allen, J.L. Severens & J. Kleijnen (2014). Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 18 (8). doi: 10.3310/hta18180
    • M.R.C. Hendriks, M.J. Al, M. Bleijlevens, J.C.M. van Haastregt, H.F.J.M. Crebolder, J.T.M. van Eijk & S.M.A.A. Evers (2013). Continuous versus intermittent data collection of health care utilization. Medical Decision Making, 33, 998-1008. doi: 10.1177/0272989X13482045
    • M.A. Kiel, E. Roder, R. Gerth van Wijk, M.J. Al, W.C.J. Hop & M.P.M.H. Rutten - van Molken (2013). Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Journal of Allergy and Clinical Immunology, 132, 353-360. doi: 10.1016/j.jaci.2013.03.013
    • P. Vemer, P.F.M. Krabbe, T.L. Feenstra, G.A.K. van Voorn, I. Corro Ramos & M.J. Al (2013). Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force. Value in Health, 16, 1106-1107. doi: 10.1016/j.jval.2013.06.015
    • M.J. Al (2013). Cost-Effectiveness Acceptability Curves Revisited. Pharmacoeconomics (Print), 31 (2), 93-100. doi: 10.1007/s40273-012-0011-8
    • L. Hakkaart-van Roijen, T.J.E.M. Bakker, M.J. Al, J. van der Lee, H.J. Duivenvoorden, M.W. Ribbe & R. Huijsman (2013). Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme. Bmc Health Services Research, 13 (370), 1-13. doi: 10.1186/1472-6963-13-370
    • I. Corro Ramos, M.P.M.H. Rutten - van Molken & M.J. Al (2013). The role of value-of-information analysis in a health care research priority setting: a theoretical case study. Medical Decision Making, 33 (4), 472-489. doi: 10.1177/0272989X12468616
    • M. Hoogendoorn, M.J. Al, K.M. Beeh, D. Bowles, J.M. Graf von der Schulenburg, J. Lungershausen, B. Monz, H. Schmidt, C. Vogelmeier & M.P.M.H. Rutten - van Molken (2013). Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. European Respiratory Journal. doi: 10.1183/09031936.00027212
    • P. Vemer, M.J. Al, M. Oppe & M.P.M.H. Rutten - van Molken (2013). A Choice That Matters? Simulation study on the impact of direct meta-analysis methods on health economic outcomes. Pharmacoeconomics (Print), 31 (8), 719-730. doi: 10.1007/s40273-013-0067-0
    • M. Hoogendoorn, M.J. Al, K.M. Beeh, D. Bowles, J.M.G. von der Schulenburg, J. Lungershausen, B. Monz, H. Schmidt, C. Vogelmeier & M.P.M.H. Rutten - van Molken (2013). Cost-effectiveness of triotropium versus salmeterol: the POET-COPD trial. European Respiratory Journal, 41 (3), 556-564. doi: 10.1183/09031936.000.27212
    • I. Corro Ramos, M.P.M.H. Rutten - van Molken & M.J. Al (2012). The Role of Value-of-Information Analysis in a Health Care Research Priority Setting: A Theoretical Case Study. Medical Decision Making. doi: 10.1177/0272989X12468616
    • E.J.I. Hoogendoorn, M.P.M.H. Rutten - van Molken, R.T. Hoogenveen, M.J. Al & T.L. Feenstra (2011). Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. Value in Health, 14 (8), 1039-1047. doi: 10.1016/j.jval.2011.06.008
    • E. Alemao, S. Rajagopalan, R.E. Curiel, J. Purvis, S. Yang & M.J. Al (2011). Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. Journal of Medical Economics, 14 (2), 245-252. doi: 10.3111/13696998.2011.566296
    • M. Oppe, M.J. Al & M.P.M.H. Rutten - van Molken (2011). Comparing Methods of Data Synthesis. Pharmacoeconomics (Print), 29 (3), 239-250. doi: 10.2165/11539870-000000000-00000
    • M.J. Al, L. Hakkaart-van Roijen, S.S. Tan & J. Bakker (2010). Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. Critical Care, 14 (195), 1-10. doi: 10.1186/cc9313
    • L. Hakkaart-van Roijen, P. Verboom, R. Philips & M.J. Al (2009). The cost utility of solifenacin in the threatment of overactive bladder. International Urology and Nephrology, 41, 293-298. doi: 10.1007/s11255-008-9448-2
    • L.M.A. Goossens, B. Standaert, N.G. Hartwig, A.M. Hovels & M.J. Al (2009). Conclusions on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine, 27, 2531-2532. doi: 10.1016/j.vaccine.2009.02.036
    • C.A.M. Boumans, A. Lintsen, M.J. Al, C. Verhaak, M.J.C. Eijkemans, J.D.F. Habbema, D.D.M. Braat & L. Hakkaart-van Roijen (2008). Absence from work and emotional stress in woman undergoing IVF or ICSI: An analysis of IVF-related absence from work in women and the contribution of general and emotional factors. Acta Obstetricia et Gynecologica Scandinavica, 87, 1169-1175. doi: 10.1080/00016340802460305
    • S.S. Tan, L. Hakkaart-van Roijen, M.J. Al, C.A.M. Boumans, M.E. Hoogendoorn, P.E. Spronk & J. Bakker (2008). A microcosting study of intensive care unit stay in the Netherlands. Journal of Intensive Care Medicine, 23 (4), 250-257. doi: 10.1177/0885066608318661
    • L.M.A. Goossens, B. Standaert, N.G. Hartwig, A.M. Hovels & M.J. Al (2008). The cost-utility of rotavirus vaccination with Rotarix TM (RIX4414) in the Netherlands. Vaccine, 26, 1118-1127. doi: 10.1016/j.vaccine.2007.11.070
    • B. van den Berg, M.J. Al, N.J.A. van Exel, M.A. Koopmanschap & W.B.F. Brouwer (2008). Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers. Value in Health, 11 (7), 1041-1050. doi: 10.1111/j.1524-4733.2008.00357.x
    • J.B. Oostenbrink, M.J. Al, M. Oppe & M.P.M.H. Rutten - van Molken (2008). Expected value of perfect information: An Empirical example of reducing decision uncertainty by conducting additional research. Value in Health, 11, 1070-1080. doi: 10.1111/j.1524-4733.2008.00389.x
    • C.M. Galani, M.J. Al, H. Schneider & F.F.H. Rutten (2008). Uncertainty in decision-making: value of additional information in the cost-effectivenss of lifestyle intervention in overweight and obese people. Value in Health, 11 (3), 424-434. doi: 10.1111/j.1524-4733.2007.00284.x
    • L.M. Lamers, R. Stupp, M.J. van den Bent, M.J. Al, T. Gorlia, J. Wasserfallen, N. Mittmann, S. Seung, R. Crott & C. Groot (2008). Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - A report from the EORTC 26981/22981 NCI-C CE3 intergroup study. Cancer, 112 (6), 1337-1344. doi: 10.1002/cncr.23297
    • M.J. Al, N. Maniadakis, E.W.M. Grijseels & M. Janssen (2008). Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands. Value in Health, 11 (4), 589-599. doi: 10.1111/j.1524-4733.2007.00303.x
    • J. Lamers, R. Stupp, M.J. van den Bent, M.J. Al, T. Gorlia, J. Wasserfallen, N. Mittmann, S. Seung, R. Crott & C.A. de Uyl-de Groot (2008). Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer, 112 (6), 1337-1344.
    • M.J. Al, T.L. Feenstra & B.A. van Hout (2005). Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Economics, 14 (7), 655-667. doi: 10.1002/hec.973
    • B. van der Berg, M.J. Al, W. Brouwer, N.J.A. van Exel & M.A. Koopmanschap (2005). Economic valuation of informal care: The conjoint measurement method applied to informal caregiving. Social Science & Medicine, 61 (6), 1342-1355. doi: 10.1016/j.socscimed.2005.01.029
    • J.B. Oostenbrink & M.J. Al (2005). The analysis of incomplete cost data due to dropout. Health Economics, 14 (8), 763-776. doi: 10.1002/hec.966
    • J.B. Oostenbrink, M.P.M.H. Rutten - van Molken, M.J. Al, J.A. Noord & W. van Vincken (2004). One-year cost-effectiveness of tiotropium to treat chronic obstructive pulmonary disease. European Respiratory Journal, 23, 241-249. doi: 10.1183/09031936.03.00083703
    • M.J. Al & W.B.F. Brouwer (2004). Decision makers views on health care objectives and budget constraints; results from a pilot. Health Policy, 70, 33-48. doi: 10.1016/j.healthpol.2004.01.009
    • P. Sendi, M.J. Al & M. Battegay (2004). Optimising the performance of an outpatient setting. Swiss Medical Weekly, 134, 44-49.
    • P. Sendi, M.J. Al & H. Zimmermann (2004). A risk-adjusted approach to comparing the return on the investment in health care programs. International Journal of Health Care Finance and Economics, 4, 199-210.
    • H.J. Bernelot Moens, J.J. Croonenborg, M.J. Al & P.M. Bemt (2004). Richtlijn 'NSAID-gebruik en preventie van maagschade'. Nederlands Tijdschrift voor Geneeskunde, 148, 604-608.
    • P. Sendi, M.J. Al, A. Gafni & S. Birch (2004). Portfolio theory and the alternative decision rule of cost- effectiveness analysis: theoretical and practical considerations. Social Science & Medicine, 58, 1853-1855. doi: 10.1016/j.socscimed.2004.01.001
    • P. Sendi, M.J. Al & F.F.H. Rutten (2004). Portfolio theory and cost- effectiveness analysis: A further discussion. Value in Health, 7, 595-601. doi: 10.1111/j.1524-4733.2004.75010.x
    • P. Sendi, M.J. Al, A. Gafni & S. Birch (2003). Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. Social Science & Medicine, 57, 2207-2215. doi: 10.1016/S0277-9536(03)00086-8
    • J.B. Oostenbrink, M.J. Al & M.P.M.H. Rutten - van Molken (2003). Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics (Print), 21, 1103-1112. doi: 10.2165/00019053-200321150-00004
    • P. Sendi & M.J. Al (2003). Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. Social Science & Medicine, 57, 969-974. doi: 10.1016/S0277-9536(02)00477-X
    • H. Suryapranata, J.P. Ottervanger, E. Nibbering, A.W.J. van 't Hof, J.C.A. Hoorntje, M.F. de Boer, M.J. Al & F. Zijlstra (2001). Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart, 85 (6), 667-671.
    • C. Chevat, B.M. Pena, M.J. Al & F.F.H. Rutten (2001). Health care resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics (Print), 19 (1), 17-32.
    • M.J. Al & B.A. van Hout (2000). A bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. Health Economics, 9, 599-609.
    • P.J. van Enckevort, E.M. TenVergert, G.J. Bonsel, A. Geertsma, W. van der Bij, W.J. Boer, M.A. Koopmanschap, M.J. Al & F.F.H. Rutten (1998). Technology Assessment of the Dutch lung transplantation program. International Journal of Technology Assessment in Health Care, 14 (2), 344-356.
    • N.F. de Keizer, G.J. Bonsel, M.J. Al & R.J.B.J. Gemke (1998). The relation between TISS and real paedeatric ICU costs: a case study with generalizable methodology. Intensive Care Medicine, 24, 1062-1069. doi: 10.1007/s001340050717
    • M.J. Al, B.A. van Hout, C.M. Bowine & F.F.H. Rutten (1998). Sample size calculation in economic evaluations. Health Economics, 7, 327-335.
    • M.J. Al, M.A. Koopmanschap, P.J. van Enckevort, A. Geertsma, W. van der Bij, W.J. Boer & E.M. ten Vergert (1998). Coast- effectiveness of lung transplantation in the Netherlands. Chest, 113 (1), 124-130.
    • B.C. Michel, M.J. Al, W.J. Remme, J.H. Kingma, J.A. Kragten, R. van Nieuwenhuizen & B.A. van Hout (1996). Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. European Heart Journal, 17 (May), 731-740.
    • M.J. Al, B.C. Michel & F.F.H. Rutten (1996). The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis. Pharmacoeconomics (Print), 10 (2), 141-151.

  • Professional Publication (5)

    • M.J. Al & W.B.F. Brouwer (2004). Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling. TSG, 82, 191-195.
    • I. Buijt, M.J. Al & F.F.H. Rutten (2003). Protonpompremmers, kostenremmers? Pharmaceutisch Weekblad, 138, 1194-1199.
    • I. Buijt, M.J. Al & F.F.H. Rutten (2003). Protonpompremmers, kostenremmers? . Pharmaceutisch Weekblad, 138, 1428-1429.
    • J.R.B.J. Brouwers, E.N. van Roon, M. Postma & M.J. Al (2000). Kosteneffectiviteit van NSAID's - Altijd gastoprotectie? Pharmaceutisch Weekblad, 135 (5), 172-175.
    • H.J. Stoevelaar & M.J. Al (1995). Medische statistiek; over getallen die leven en worden geleefd. Klinische Fysica, 1 (1), 25-29.

• Report (5)

  • Scholarly Publication (2)

    • P. Whiting, M.J. Al, M. Westwood, I. Corro Ramos, S. Ryder, N. Armstrong, K. Misso, J. Ross, J.L. Severens & J. Kleijnen (2016). Viscoelastic point-of-care testing to assist with the diagnosis management and monitoring of haemostasis a systematic review and cost-effectiveness analysis. (Extern rapport, 19, no 58). : Health Technology Assessment
    • R. Riemsma, M.J. Al, I. Corro Ramos, S.N. Deshpande, N. Armstrong, Y.C. Lee, S. Ryder, C. Noake, M. Krol, M. Oppe, J. Kleijnen & J.L. Severens (2013). SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. (Extern rapport). Southampton: National Institute for Health Research

  • Professional Publication (2)

    • M. Westwood, M.J. Al, L.T. Burgers, W.K. Redekop, S.K. Lhachimi, N. Armstrong, H. Raatz, K. Misso, J.L. Severens & J. Kleijnen (2013). A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. (Extern rapport, 17, no 9). United Kingdon: Health Technology Assessment
    • M. Hoogendoorn, M.P.M.H. Rutten - van Molken, R. Hoogeveen, M.J. Al & T.L. Feenstra (2010). Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD. (Intern rapport). Rotterdam: iBMG

  • Other Publication (1)

    • M.J. Al (1995). Hulpambulances nader beschouwd. (Extern rapport). Den Haag: Begeleidingscommissie experiment hulpambulancevervoer

• Part of book - Chapter (1)

  • M.J. Al (2000). Modelleren en omgaan met onzekerheid. In M.P.M.H. Rutten- van Mölken, J.J. van Busschbach & F.F.H. Rutten (Eds.), Van kosten tot effecten (pp. 107-122). Maarssen: Elsevier gezondheidszorg

• Doctoral thesis (1)

  • M.J. Al (2001, oktober 11). Certain methods for uncertain situations. Evaluating health care technologies. EUR Prom./coprom.: Dr. B.A. van Hout & prof.dr. F.F.H. Rutten.

• Supervised Theses (3)

  • E. Alemao (2018, juni 13). Future Economic Evaluations in Rheumatoid Arthritis : a case for considering comprehensive benefits and costs of interventions. EUR Prom./coprom.: Prof. Dr. M.P.M.H. Rutten-van Mölken & dr. M.J. Al.
  • C.M. Galani (2009, februari 12). Health Technology Assessment of Medical Interventions in the Prevention and Treatment of Disease DIrections of Further Research and Policy Implications. EUR (193 pag.) (Rotterdam) Prom./coprom.: prof.dr. F.F.H. Rutten & dr. M.J. Al.
  • M.J.C. Nuijten (2003, maart 26). In search for more confidence in health economic modeling: reducing uncertainty associated with modeling studies. EUR (208 pag.) Prom./coprom.: prof.dr. F.F.H. Rutten & dr. M.J. Al.

Teaching (8)

Present position

Other positions (1)